Zobrazeno 1 - 10
of 263
pro vyhledávání: '"Antonio, Omuro"'
Autor:
Antonio Omuro
Publikováno v:
Arquivos de Neuro-Psiquiatria, Vol 80, Iss 5 suppl 1, Pp 266-269 (2022)
ABSTRACT Background: Glioblastoma, the most common malignant primary brain tumor, remains a lethal disease with few therapeutic options. Immunotherapies, particularly immune checkpoint inhibitors (ICPi), have revolutionized cancer treatment, but thei
Externí odkaz:
https://doaj.org/article/8d832fd4720d471ab47c25ad3ff4b82a
Autor:
Enoch Chang, Marina Z. Joel, Hannah Y. Chang, Justin Du, Omaditya Khanna, Antonio Omuro, Veronica Chiang, Sanjay Aneja
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract Radiomic feature analysis has been shown to be effective at analyzing diagnostic images to model cancer outcomes. It has not yet been established how to best combine radiomic features in cancer patients with multifocal tumors. As the number
Externí odkaz:
https://doaj.org/article/59853435739a456ba6fef22045cf3adb
Autor:
Thomas J. Kaley, Katherine S. Panageas, Elena I. Pentsova, Ingo K. Mellinghoff, Craig Nolan, Igor Gavrilovic, Lisa M. DeAngelis, Lauren E. Abrey, Eric C. Holland, Antonio Omuro, Mario E. Lacouture, Emmy Ludwig, Andrew B. Lassman
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 7, Iss 4, Pp 429-436 (2020)
Abstract Purpose Malignant glioma (MG) is the most deadly primary brain cancer. Signaling though the PI3K/AKT/mTOR axis is activated in most MGs and therefore a potential therapeutic target. The mTOR inhibitor temsirolimus and the AKT inhibitor perif
Externí odkaz:
https://doaj.org/article/12a34fde3fdf4d90a2d5bd4a3dc14ad8
Autor:
Mayu O. Frank, Takahiko Koyama, Kahn Rhrissorrakrai, Nicolas Robine, Filippo Utro, Anne-Katrin Emde, Bo-Juen Chen, Kanika Arora, Minita Shah, Heather Geiger, Vanessa Felice, Esra Dikoglu, Sadia Rahman, Alice Fang, Vladimir Vacic, Ewa A. Bergmann, Julia L. Moore Vogel, Catherine Reeves, Depinder Khaira, Anthony Calabro, Duyang Kim, Michelle F. Lamendola-Essel, Cecilia Esteves, Phaedra Agius, Christian Stolte, John Boockvar, Alexis Demopoulos, Dimitris G. Placantonakis, John G. Golfinos, Cameron Brennan, Jeffrey Bruce, Andrew B. Lassman, Peter Canoll, Christian Grommes, Mariza Daras, Eli Diamond, Antonio Omuro, Elena Pentsova, Dana E. Orange, Stephen J. Harvey, Jerome B. Posner, Vanessa V. Michelini, Vaidehi Jobanputra, Michael C. Zody, John Kelly, Laxmi Parida, Kazimierz O. Wrzeszczynski, Ajay K. Royyuru, Robert B. Darnell
Publikováno v:
BMC Medical Genomics, Vol 12, Iss 1, Pp 1-16 (2019)
Abstract Background Prompted by the revolution in high-throughput sequencing and its potential impact for treating cancer patients, we initiated a clinical research study to compare the ability of different sequencing assays and analysis methods to a
Externí odkaz:
https://doaj.org/article/11a5273709844f08a3cc53b25ce39717
Autor:
Kristina Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott Boerner, Jing Li, Diane Durecki, Jan Drappatz, Vinay Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, S. Percy Ivy, Ranjit S. Bindra, Antonio Omuro, Patricia LoRusso
Publikováno v:
Cancer Research Communications. 3:192-201
Purpose: Isocitrate dehydrogenase (IDH) 1 and IDH2 mutations (IDH1/2mt) are frequent in glioma. Preclinical studies suggest IDH1/2mts confer “BRCAness” phenotype, a vulnerability that can be targeted through PARP inhibition. To test this hypothes
Autor:
Antonio Omuro, Alba A Brandes, Antoine F Carpentier, Ahmed Idbaih, David A Reardon, Timothy Cloughesy, Ashley Sumrall, Joachim Baehring, Martin van den Bent, Oliver Bähr, Giuseppe Lombardi, Paul Mulholland, Ghazaleh Tabatabai, Ulrik Lassen, Juan Manuel Sepulveda, Mustafa Khasraw, Elodie Vauleon, Yoshihiro Muragaki, Anna Maria Di Giacomo, Nicholas Butowski, Patrick Roth, Xiaozhong Qian, Alex Z Fu, Yanfang Liu, Von Potter, Alexandros-Georgios Chalamandaris, Kay Tatsuoka, Michael Lim, Michael Weller
Publikováno v:
Neuro-Oncology, 25(1), 123-134. Oxford University Press
Background Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with tumors harboring an unmethylated MGMT promoter derive minimal benefit.
Publikováno v:
CNS Oncology, Vol 7, Iss 1, Pp 7-13 (2018)
Interpretation of MRI abnormalities in patients with malignant gliomas (MG) treated with bevacizumab is challenging. Recent reports describe quantitative analyses of diffusion-weighted imaging abnormalities not available in standard clinical settings
Externí odkaz:
https://doaj.org/article/b5aea353474c4ffcb7fa4b6dd57aa5c9
Autor:
Manpreet Kaur, Gabriel Cassinelli, Marc von Reppert, Leon Jekel, Sunitha Varghese, Irene Dixe, Antonio Omuro, Veronica Chiang, Mariam Aboian
Publikováno v:
Wednesday, April 26.
Autor:
Patricia LoRusso, Antonio Omuro, Ranjit S. Bindra, S. Percy Ivy, Pierre Giglio, Javier Gonzalez, Frank Scott Lieberman, Vinay Puduvalli, Jan Drappatz, Diane Durecki, Jing Li, Scott Boerner, Yu Shyr, Derek Shyr, Mary Jo Pilat, Kristina Fanucci
Representativeness of Study Participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0df51c6bc3f4ac79ca4a3c83d4e7c11
https://doi.org/10.1158/2767-9764.22545912.v1
https://doi.org/10.1158/2767-9764.22545912.v1
Autor:
Patricia LoRusso, Antonio Omuro, Ranjit S. Bindra, S. Percy Ivy, Pierre Giglio, Javier Gonzalez, Frank Scott Lieberman, Vinay Puduvalli, Jan Drappatz, Diane Durecki, Jing Li, Scott Boerner, Yu Shyr, Derek Shyr, Mary Jo Pilat, Kristina Fanucci
Definition of Progression, Tumor Classification, and Eligibility Criteria, retreatment criteria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38051cb61c7f9e35bbffa7887c372133
https://doi.org/10.1158/2767-9764.22545915
https://doi.org/10.1158/2767-9764.22545915